The experience for the use of PD-L1 as a prognostic marker in cancers has been mixed [24]; PD-L1 tumour expression has correlated with poorer outcome in breast [27] and renal [28, 29] but better survival in lung cancer [30]. This evidence concerns the gene CD274 and lung carcinoma.